Your session is about to expire
← Back to Search
Chemoradiation + Chemotherapy for Cervical Cancer
Study Summary
This trial is testing paclitaxel and carboplatin as a follow-up to cisplatin and radiation therapy for cervical cancer patients to see if it is more effective in killing tumor cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 3 trial • 256 Patients • NCT01005680Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had any cancer other than non-melanoma skin cancer in the last 5 years.I have had radiation, chemotherapy, or any treatment for my cancer before.I have a unique kidney condition that affects how radiation therapy is given.I haven't had serious heart problems in the last 6 months.My kidney function, measured by creatinine levels, is within the normal range.I have had a stent or tube placed for my blocked ureter before joining the study.My cervical cancer is confirmed and has spread to the lymph nodes near my aorta.I will have a hearing test before starting treatment and often if I already have or develop hearing loss.I currently have an active infection.I can take care of myself but might not be able to do heavy physical work.I have not had major surgery, except for a biopsy, in the last 30 days.My nerve damage symptoms are mild or not present.You have had allergic reactions to products that contain Cremophor EL.
- Group 1: Treatment (radiation, cisplatin, paclitaxel, carboplatin)
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many sites can this trial be accessed?
"In total, 14 clinical sites are participating in this study. Examples include the University of Iowa/Holden Comprehensive Cancer Center (Iowa City), Cleveland Clinic Foundation (Cleveland) and University of Oklahoma Health Sciences Centre (Oklahoma City)."
Are there vacancies available in this clinical trial for volunteers?
"The recruitment for this particular study has been suspended since 3/8/2019. If you are looking to join other trials, 2866 medical studies related to adenocarcinoma and 1,571 examinations involving Cisplatin have open enrollments at present."
Have there been any other research endeavors involving Cisplatin?
"Cisplatin was first investigated at City of Hope Comprehensive Cancer Center in 1997 and has since amassed 2330 completed clinical trials. In the present day, 1571 active studies are being conducted with numerous sites located in Iowa City, Iowa."
What illnesses does Cisplatin typically target?
"Generally, cisplatin is assigned to address advanced cases of endometrial cancer. However, it may also be used as a remedy for melanoma, neoplasm metastasis, lymphoma and non-Hodgkin's disease."
What side effects have been observed from Cisplatin treatment?
"Due to the limited research done on Cisplatin, we have assigned it a safety score of 1. This is in line with Phase 1 trial standards as there has been little evidence indicating its efficacy or safety."
How many individuals are currently participating in the research study?
"This investigation is no longer accepting new applicants, having been first posted on April 4th 2011 and last updated March 8th 2019. If you are searching for alternative trials to join, there currently exist 2866 adenocarcinoma studies recruiting patients and 1571 Cisplatin experiments that require volunteers."
Share this study with friends
Copy Link
Messenger